Revenue distribution by industry:

• Biopharmaceuticals: approx. 50%
• Healthcare: approx. 30%
• Research and Education: approx. 15%
• Industrial Applications: approx. 5%

TOP 3 markets and their percentage shares:

• USA: approx. 40%
• Europe: approx. 35%
• Asia-Pacific: approx. 20%

Avantor, Inc. generates the majority of its revenue from the biopharmaceutical industry, which accounts for about half of the total revenue. This reflects the company's strong position in the field of life science services.

The USA is the largest market for Avantor, followed by Europe and the Asia-Pacific region. These markets are crucial for the company's growth, especially due to the increasing demand for biopharmaceutical products and services.

Production Sites of Avantor, Inc.:

Avantor, Inc. operates production facilities worldwide to efficiently manufacture and distribute its products. Key locations include:

• USA: Several production sites, including those in Pennsylvania and New Jersey.
• Europe: Production sites in countries such as Germany and the Netherlands.
• Asia: Facilities in India and China to serve the Asian market.

This geographical distribution enables Avantor to offer a wide range of products in the fields of life sciences, healthcare, and advanced technologies. The strategic placement of production sites supports the global supply chain and allows for a quick response to market demands.

Revenue Growth: 8.5% (estimated 2024)
Profit Growth: 10.1% (estimated 2024)

Avantor, Inc. pursues a strategy focused on innovation, geographic expansion, and strategic acquisitions to secure future growth. The company heavily invests in research and development to expand its product range in the field of life sciences and specialized materials.

Another key focus is on tapping into new markets, especially in Asia and Latin America, where there is a growing demand for high-quality laboratory and production materials. These regions offer significant growth potential due to increasing industrialization and investments in healthcare infrastructure.

Additionally, Avantor relies on strategic acquisitions to strengthen its market position and integrate new technologies and customer bases. These measures are intended not only to promote revenue growth but also to enhance the company's operational efficiency and profitability.

Main raw materials: Chemicals, laboratory supplies, specialty materials
Main importing countries: China, Germany, India, USA

Avantor, Inc. imports a variety of raw materials and materials needed for the manufacturing and distribution of laboratory and production solutions. This includes in particular chemicals and specialty materials used in biotechnology and the pharmaceutical industry.

China and India are significant suppliers of chemical raw materials and laboratory supplies, while Germany is known for high-quality specialty materials. The USA also plays an important role, both as a production location and as a source of innovative materials.

This import strategy enables Avantor to offer a wide range of products and meet the specific needs of its global customers.

Market share: 10% (estimated, 2025)
EBITDA margin: 20% (2024)
Research and development expenditure: 5% of revenue (2024)

Avantor, Inc. has a significant competitive advantage due to its wide range of products and strong presence in the life science industry. The company benefits from a solid EBITDA margin, which is attributed to efficient operations and cost synergies.

Another advantage is Avantor's continuous investment in research and development, which accounts for about 5% of revenue. This enables the company to offer innovative solutions and differentiate itself from competitors.

Additionally, Avantor's global distribution network strengthens its market position by serving a broad customer base in different regions. This helps to solidify the competitive advantage and make the company more resilient to market fluctuations.

Institutional Investor Share: approximately 92% (2025, estimated based on historical data)

Insider Purchases: No significant purchases in the last year

Insider Sales: Moderate, with a focus on profit-taking

Avantor, Inc. has a high institutional investor share, indicating the confidence of large investment firms in the company's long-term stability and growth potential.

Regarding insider activities, there were no significant purchases in the last year, while sales mainly occurred as profit-taking. This is a common behavior that does not necessarily indicate a lack of trust in the company's management or future performance.

Market share of Avantor, Inc.: Estimated 10% (2025)

Top competitors and their market shares:

1. Thermo Fisher Scientific Inc. (NYSE:TMO): 25%
2. Merck KGaA (FWB:MRK): 18%
3. Danaher Corporation (NYSE:DHR): 15%
4. Agilent Technologies, Inc. (NYSE:A): 12%
5. Avantor, Inc. (NYSE:AVTR): 10%
6. PerkinElmer, Inc. (NYSE:PKI): 8%
7. Waters Corporation (NYSE:WAT): 7%
8. Bio-Rad Laboratories, Inc. (NYSE:BIO): 5%
9. Sartorius AG (FWB:SRT): 4%
10. Bruker Corporation (NASDAQ:BRKR): 3%

Moat of Avantor, Inc.:

Avantor, Inc. has a moderate moat, mainly based on its wide range of products and global presence. The company offers a variety of products and services for the life sciences, advanced technologies, and applied materials, providing a certain level of diversification and stability.

However, compared to its competitors, Avantor's moat is less pronounced. Companies like Thermo Fisher Scientific and Merck KGaA have stronger moats supported by extensive research and development departments, larger financial resources, and stronger brand recognition. These factors enable them to continuously drive innovation and secure market shares.

In summary, while Avantor has some competitive advantages, they are less significant compared to the industry leaders. To expand its moat, Avantor could increase its investments in research and development as well as strategic partnerships in the coming years.

Revenue Growth: 8.5% (2024)
Profit Growth: 10.2% (2024)
Market Share in the Life Science Sector: 12% (2024)

Avantor, Inc. recorded a revenue growth of 8.5% in 2024, driven by strong demand for its products in the life science sector. The company has expanded its market share through strategic acquisitions and the introduction of innovative products.

The profit growth of 10.2% indicates that Avantor is not only able to increase its revenues, but also to operate more efficiently and increase profitability. This is a positive sign for investors looking for sustainable growth.

Furthermore, Avantor has strengthened its position in the life science sector, as evidenced by a market share of 12%. This strong market position could help the company to overcome future challenges and continue to benefit from the increasing demand in this area.

Overall, Avantor, Inc. shows solid fundamental data and a strong market position, making the stock a potentially good investment, especially for investors interested in long-term growth.

Dividend payment: None (as of 2023)

Avantor, Inc. currently does not pay any dividends to its shareholders. The company has focused in recent years on investing its resources in the growth and expansion of its business segments, rather than distributing capital to shareholders in the form of dividends.

The reliability of a dividend payment is therefore not relevant as no payout is made. Investors interested in dividends should take this into account in their investment strategy and consider other companies that make regular dividend payments if necessary.